by qfrsolutions | Jan 18, 2017 | News
Source: Globe Newswire Novan, Inc. (“the Company” or “Novan”) (NOVN) today announced that the Company has entered into an exclusive license agreement with Sato Pharmaceutical Co., Ltd. (“Sato”), a Japanese company with a...
by qfrsolutions | Jan 4, 2017 | News
Source: Sun Pharma announced successful Phase 3 confirmatory clinical trial results for Seciera™ (cyclosporine A, 0.09% ophthalmic solution), for the treatment of dry eye disease. Seciera™ is a patented, novel, proprietary nanomicellar formulation of...
by qfrsolutions | Dec 14, 2016 | News
Source: Reuters The U.S. Food and Drug Administration on Wednesday said it approved Pfizer Inc’s (PFE.N) ointment to treat mild to moderate cases of the itchy skin condition eczema, or atopic dermatitis, for use in patients aged two years and older. Atopic...
by qfrsolutions | Dec 13, 2016 | News
Source: PR Newswire Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant” or the “Company”) today announced that William D. Humphries has been appointed Executive Vice President, Dermatology, effective January 2, 2017....
by qfrsolutions | Dec 9, 2016 | News
Source: Aclaris Therapeutics’ investigational new drug (IND) application for ATI-50001, an orally administered investigational Janus Kinase (JAK) inhibitor, for the potential treatment of alopecia totalis and alopecia universalis has cleared the 30-day review...
by qfrsolutions | Dec 1, 2016 | News
Source: Globe Newswire Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced top-line results from the Company’s Phase 2 clinical trial with SB206 for the treatment of genital warts caused by human papillomavirus, or HPV....
